Ongoing strength in the key China market has prompted a positive trading update, indicating FY21 revenues and EBITDA will be significantly ahead of (already upgraded) expectations. Demand for Aivlosin in China in particular has remained strong throughout Q3 and is expected to remain so in Q4. We upgrade our FY21 revenue forecasts by 12% to £91.9m, which flows through to a 30% PBT upgrade to £10.1m. Whilst there is some caution expressed over the sustainability of this demand, we now forecast a f ....
21 Jan 2021
Continued China strength prompts further upgrades
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Continued China strength prompts further upgrades
ECO Animal Health Group plc (EAH:LON) | 102 8.7 9.0% | Mkt Cap: 69.4m
- Published:
21 Jan 2021 -
Author:
Chris Glasper | Edward Thomason -
Pages:
4
Ongoing strength in the key China market has prompted a positive trading update, indicating FY21 revenues and EBITDA will be significantly ahead of (already upgraded) expectations. Demand for Aivlosin in China in particular has remained strong throughout Q3 and is expected to remain so in Q4. We upgrade our FY21 revenue forecasts by 12% to £91.9m, which flows through to a 30% PBT upgrade to £10.1m. Whilst there is some caution expressed over the sustainability of this demand, we now forecast a f ....